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DOT1 (disruptor of telomeric silencing; also called
Kmt4) was initially discovered in budding yeast in a genetic
screen for genes whose deletion confers defects in telo-
meric silencing. Since the discovery ~10 years ago that
Dot1 and its mammalian homolog, DOT1L (DOT1-Like),
possess histone methyltransferase activity toward histone
H3 Lys 79, great progress has been made in characterizing
their enzymatic activities and the role of Dot1/DOT1L-
mediated H3K79 methylation in transcriptional regula-
tion, cell cycle regulation, and the DNA damage response.
In addition, gene disruption in mice has revealed that
mouse DOT1L plays an essential role in embryonic de-
velopment, hematopoiesis, cardiac function, and the de-
velopment of leukemia. The involvement of DOT1L
enzymatic activity in leukemogenesis driven by a subset
of MLL (mixed-lineage leukemia) fusion proteins raises
the possibility of targeting DOT1L for therapeutic
intervention.
Eukaryotic DNA is wrapped around a histone octamer
(H3/H4 heterotetramer and two H2A/H2B dimers) to
form the nucleosome, the fundamental building block of
chromatin (Van Holde et al. 1980; Luger et al. 1997;
Kornberg and Lorch 1999; Zhang and Dent 2005). His-
tone proteins are subject to reversible post-translational
modifications, which play an important role in the
establishment and maintenance of gene expression pat-
terns within any given cell type of an organism. Studies
in the past decade have established that covalent histone
modifications influence chromatin structure and func-
tion directly or indirectly through the recruitment of
effector proteins to specific chromatin regions (Strahl
and Allis 2000; Martin and Zhang 2005; Kouzarides
2007).
One of the covalent histone modifications is methyla-
tion, which takes place on both lysine (K) and arginine (R)
residues (Zhang and Reinberg 2001; Martin and Zhang
2005). Lysine methylation exists in mono, di, and tri
states, while arginine methylation only occurs in mono
and di states. One way that these methyl marks contrib-
ute to transcriptional regulation is to serve as a platform
for the recruitment of effector proteins. The well-studied
lysine methylation residues include K4, K9, K27, K36,
and K79 of histone H3, and K20 of histone H4. In general,
methylation at H3K9, H3K27, and H4K20 correlates with
transcriptional repression, while methylation at H3K4,
H3K36, and H3K79 correlates with gene transcription
(Kouzarides 2002; Peterson and Laniel 2004; Martin and
Zhang 2005). In addition to its role in transcriptional
regulation, methylation has also been linked to X inacti-
vation, cell fate determination, terminal differentiation,
and the spatiotemporal patterning of Hox genes (Cavalli
2006; Minard et al. 2009). Moreover, aberrant histone
methylation has also been linked to various human can-
cers (Feinberg et al. 2002; Handel et al. 2010).
Histone methylation is catalyzed by a group of histone
methyltransferases. Based on their catalytic domains, the
lysine methyltransferases (KMTs) that have been charac-
terized to date can be divided into two classes. The first
class contains an evolutionarily conserved SET {Su(var)3-
9, Enhancer of Zeste ½E(Z), and Trithorax (trx)} domain
(Jenuwein et al. 1998). In contrast, the second class does
not possess a SET domain and consists of only an evo-
lutionarily conserved protein named Dot1 (disruptor of
telomeric silencing; also called Kmt4) (Singer et al. 1998)
and its homologs in other organisms (Feng et al. 2002;
Lacoste et al. 2002; van Leeuwen et al. 2002). Dot1 and its
homologs contain a catalytic methylase fold resembling
that of class I methylases (Ng et al. 2002a; Min et al. 2003;
Schubert et al. 2003). Over the years, great progress has
been made in elucidating the function of Dot1 and its
associated H3K79 methylation mark in various organ-
isms and cellular processes. Here we summarize these
studies with an emphasis on Dot1’s enzymatic activity
and its diverse biological functions.
Dot1/DOT1L (DOT1-Like) enzymatic activity
and its regulation
Dot1 and its homologs possess H3K79
methyltransferase activity
Using different approaches, several groups independently
discovered that Lys 79 within the globular domain of
histone H3 (H3K79) is subject to methylation, and that
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the yeast protein Dot1 and its human homolog, DOT1L,
are responsible for catalyzing the methylation reaction
(Feng et al. 2002; Lacoste et al. 2002; Ng et al. 2002a; van
Leeuwen et al. 2002). Both enzymes are capable of
catalyzing mono-, di-, and trimethylation in a nonproces-
sive manner (Min et al. 2003; Frederiks et al. 2008). Dot1
and its homologs appear to be solely responsible for
H3K79 methylation, since knockout of Dot1 in yeast,
flies, and mice results in complete loss of H3K79 meth-
ylation (van Leeuwen et al. 2002; Shanower et al. 2005;
Jones et al. 2008).
Dot1 homologs share a conserved region with four
sequence motifs—I, post I, II, and III—found in SAM
methyltransferases (Fig. 1A). The crystal structures of
both yeast Dot1and human DOT1L also reveal an open
a/b structure composed of a seven-stranded b sheet that
Figure 1. Dot1 is a conserved class I SAM-dependent methylase. (A) Sequence alignment of the conserved catalytic core region of
Dot1 across multiple species that include yeast (NP_010728), worm (NM_058569), fly (AE003675), mouse (BB678539), and human
(NP_115871). Secondary structure elements are shown above the alignment. The dashed line indicates disordered regions. Invariant
amino acids are shown in white letters against a gray background, while conserved residues are in bold. Amino acids conserved across
all five species are in bold against a green background. Every 10 amino acids is marked by a plus sign. The conserved methyltransferase
fold motifs—I, post I, II, and III—are labeled and boxed in red. (B) The crystal structure of the substrate-binding pocket of human
DOT1L (Protein Data Bank ½PDB code 1NW3) demonstrates that it is more similar to that of rat PRMT1 (PDB code 1ORI), a class I
arginine methyltransferase, than to the KMT hNSD1 (PDB code 3OOI).
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is characteristic of the class I SAM-dependent methyl-
transferases (Fig. 1B; Cheng and Roberts 2001; Min et al.
2003; Sawada et al. 2004). Despite the fact that both
human and yeast Dot1 proteins are structurally more
similar to arginine methyltransferases (Fig. 1B), members
of the Dot1 family proteins catalyze histone lysine meth-
ylation rather than arginine methylation (Feng et al. 2002;
Lacoste et al. 2002; van Leeuwen et al. 2002; Zhang et al.
2004; Shanower et al. 2005). Due to the structural simi-
larities between Dot1 and arginine methyltransferases
(Fig. 1B), there has been some speculation as to whether
Dot1 can also catalyze arginine methylation. However,
extensive efforts using reverse-phase high-performance
liquid chromatography (HPLC) coupled with nano-liquid
chromatography electrospray ionization mass spectrome-
try (LC-ESMS) and tandem mass spectrometry (MS/MS)
have failed to demonstrate that Dot1 has arginine meth-
yltransferase activity (van Leeuwen et al. 2002).
Interplay between H2B ubiquitination
and H3K79 methylation
Characterization of DOTL enzymatic activity indicated
that it preferentially methylates H3K79 in the context of
nucleosomes rather than core histones or recombinant
H3 (Feng et al. 2002). This observation suggests that
DOT1L may recognize other features of the nucleosome.
Based on nucleosome structure, K79 lies within loop 1 of
histone H3, which is solvent-accessible and lies adjacent
to the interface between the H3/H4 tetramer and H2A/
H2B dimer (Luger et al. 1997). This unique position of
H3K79 and the preference of DOT1L for nucleosomal
substrates suggested that trans-histone cross-talk may
play a role in regulating DOT1L enzymatic activity,
which indeed turned out to be the case.
In yeast, histone H2B can be monoubiquitinated at Lys
123 (H2B-K123ub). This modification is catalyzed by the
ubiquitin-conjugating E2 enzyme Rad6 and the ubiquitin
E3 ligase Bre1 (Robzyk et al. 2000; Wood et al. 2003a).
Bre1 not only serves as an E3 ligase for H2B ubiquitina-
tion, but is also required for the recruitment of Rad6 to
chromatin (Wood et al. 2003a). Interestingly, both H3K79
and H2B-K123 lie in proximity on the same exposed nu-
cleosome surface (Luger et al. 1997), which provides a
structural basis for an interplay between the two modi-
fications (Fig. 2A). Consistently, deletion of Rad6 and
members of the Paf1 complex not only blocked H2B
ubiquitination, but also prevented H3K4 and H3K79
methylation (Briggs et al. 2002; Ng et al. 2002b; Sun and
Allis 2002). Furthermore, mutation of H2B-K123 also
prevented H3K79 and H3K4 methylation, indicating that
H2B ubiquitination is a prerequisite for H3K79 and H3K4
methylation (Briggs et al. 2002; Ng et al. 2002b, 2003b;
Sun and Allis 2002; Krogan et al. 2003; Wood et al. 2003b).
This effect appears to be unidirectional, as deletion of
Dot1 does not affect H2B ubiquitination (Sun and Allis
2002). Additionally, the relationship between H2B ubiq-
uitination and histone methylation is residue-dependent,
as H3K36 methylation is not affected by Rad6 deletion
(Briggs et al. 2002; Ng et al. 2002b).
The critical role of H2B ubiquitination in mediat-
ing H3K79 methylation raised the question of how H2B
Figure 2. Ubiquitination of yH2B-K123/hH2B-K120
regulates Dot1-mediated H3K79 methylation. (A) The
crystal structure of the human nucleosome (PDB code
3AFA) is shown on the left. Histone H2A is shown in
light green, H4 is shown in sand, H2B is shown in hot
pink, and H3 is shown in blue. A close-up view of the
nucleosome surface is on the right, with the location of
H2B-K120 shown as yellow spheres and H3K79 shown
as green spheres. Note that H2B-K120 and H3K79 are
located in proximity on the same solvent-exposed surface
of the nucleosome. (B) Proposed models for trans-histone
regulation of Dot1 enzymatic activity by H2B-K123ub.
Histone H2B-K123 ubiquitination is mediated by the
ubiquitin-conjugating enzyme Rad6 and its E3 ubiquitin
ligase, Bre1. Components of the Paf1 complex are re-
quired for efficient H2B ubiquitination and di- and
trimethylation of H3K4 and H3K79. (Bottom left) The
first model suggests that Dot1 can bind directly to H2B-
K123ub for intranucleosomal H3K79 methylation. (Top
right) The second model suggests that other factors, such
as the Set1-containing COMPASS, are required to bridge
the interaction between Dot1 and the nucleosome. Rtf1
of the Paf1 complex recruits the COMPASS complex to
methylate H3K4. The Cps35 subunit of the COMPASS
interacts directly with H2B-K123 and Dot1, thus bringing
Dot1 to the nucleosome for H3K79 methylation. (Bottom
right) In the third model, ubiquitination of H2B causes
a conformational change to the nucleosome, making
H3K79 more accessible to DOT1.
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ubiquitination contributes to H3K79 methylation. Three
mutually nonexclusive possibilities have been proposed.
They include (1) indirect interaction between Dot1 and
H2B-K123ub through a bridging protein, (2) direct interac-
tion between Dot1 and H2B-K123ub, and (3) that ubiquiti-
nation of H2B causes chromatin structure changes to
facilitate Dot1-mediated H3K79 methylation. Published
evidence supports the use of all three mechanisms. For
example, H2Bub can recruit Rpt4 and Rpt6 to chromatin
to facilitate H3K79 methylation (Ezhkova and Tansey
2004). In addition, Cps35, a component of the Set1 (also
called Kmt2)-containing COMPASS complex, interacts
directly with both H2B-K123ub and Dot1 and is required
for H3K79 trimethylation (Lee et al. 2007). These studies
suggest that ubiquitinated H2B indirectly recruits Dot1
to methylate H3K79 through some bridging factors (Fig.
2B, top right). On the other hand, Dot1 can interact
directly with ubiquitin through a lysine-rich region
(amino acids 101–140) within the N terminus of Dot1,
which is also required for nucleosome binding, and de-
letion of this region resulted in reduced di- and trimethy-
lation (Oh et al. 2010). In addition, chemically engineered
ubiquitinated H2B has been shown to stimulate intra-
nucleosomal H3K79 methylation by DOT1L without the
presence of other bridging factors (Fig. 2B, bottom left;
McGinty et al. 2008; Chatterjee et al. 2010). Finally, in
support of the third mechanism, it was shown that
ubiquitination of H2B can disrupt chromatin compac-
tion and interchromatin fiber interactions to increase
substrate accessibility (Fig. 2B, bottom right; Fierz et al.
2011). This contradicts a previous study demonstrating
that H2B ubiquitination regulates nucleosome stability
rather than chromatin conformation (Chandrasekharan
et al. 2009). The discrepancy between the two studies
may be caused by the use of different substrates. Muir and
colleagues (Fierz et al. 2011) used chemically engineered
and reconstituted nucleosomal substrates, whereas Sun
and colleagues (Chandrasekharan et al. 2009) used mod-
ified nucleosomes purified from different mutant yeast
strains. In summary, current literature supports the pro-
posal that several mutually nonexclusive mechanisms,
illustrated in Figure 2B, are used for the regulation of
H3K79 methylation by H2B ubiquitination.
Reversibility of H3K79 methylation
Although the establishment of H3K79 methylation is
well characterized and is highly regulated by multiple
processes, active demethylation of this mark is less well
understood. Thus far, with the exception of H3K79, all
other known histone lysine residues subject to methyla-
tion can be demethylated by at least one histone demeth-
ylase (Klose et al. 2006; Klose and Zhang 2007; Cloos et al.
2008; Liu et al. 2010; Qi et al. 2010). However, several
lines of evidence suggest that H3K79 methylation might
be reversible, as it is subject to dynamic regulation. First,
in yeast and human cells, the H3K79me2 methylation
level fluctuates with the cell cycle (Feng et al. 2002;
Schulze et al. 2009). Second, H3K79me2 is demethylated
during early embryonic development in both mice and
flies, suggesting that an inactive demethylase might re-
side in mature oocytes (Shanower et al. 2005; Ooga et al.
2008). Third, a study investigating the antagonistic ef-
fects of 2-hydroxyglutarate (2-HG) on a-KG (a cofactor for
dioxygenases that include the JmjC domain-containing
histone demethylases and the TET family of 5-methyl-
cytosine hydroxylases) demonstrated that global levels of
H3K79me2 increased in the presence of synthetic 2-HG
and mutant isocitrate dehydrogenase (IDH), a NADP-
dependent enzyme that catalyzes the oxidative decarbox-
ylation of isocitrate to a-KG. These observations sug-
gest that a dioxygenase may catalyze the removal of
H3K79me2 marks in vivo (Xu et al. 2011). We anticipate
that it may not be too long before the identity of this
elusive H3K79-specific demethylase is revealed.
Dot1-mediated H3K79 methylation
in transcriptional regulation
Dot1 and telomeric silencing
in Saccharomyces cerevisiae
Four years prior to the characterization of Dot1’s enzy-
matic activity, DOT1 was identified in a genetic screen
for genes whose overexpression disrupts telomeric silenc-
ing. The establishment of telomere and telomere-proxi-
mal DNA silencing is achieved through the recruitment
and binding of Sir (silent information regulator) proteins
(Norris and Boeke 2010). Interestingly, overexpression
and deletion of Dot1, as well as mutation of H3K79, com-
promise the silencing at telomeres and HML/HMR loci.
In all three cases, the level of Sir proteins bound at telo-
meres is reduced, thus limiting their ability to silence
genes. Sir3 interacts with H3K79 through its N-terminal
BAH domain, and this interaction is impeded by H3K79
methylation, and, consequently, Sir3 binding and spread-
ing of heterochromatin is affected (Katan-Khaykovich
and Struhl 2005; Onishi et al. 2007; van Welsem et al.
2008). Reciprocally, Sir3 inhibits H3K79 methylation by
competing with Dot1 for binding to the same basic patch
of histone H4 that is required for Dot1 enzymatic activity
(Altaf et al. 2007; Fingerman et al. 2007). Thus, balancing
the amount of Sir protein binding and the level of H3K79
methylation is important for regulating heterochromatin
formation at telomeres.
We note that, in these previous studies, reporter sys-
tems were used to draw general conclusions about Dot1-
mediated H3K79 methylation and telomere silencing.
Interestingly, two recent studies challenge the role of
Dot1 in heterochromatin formation. Employing the URA3
telomere reporter system, Rossmann et al. (2011) dem-
onstrated that the variegated silencing observed in Dot1
mutants is due to a disproportion in ribonucleotide re-
ductase and the promoter of URA3 at telomere VII–L
rather than a requirement for Dot1 in general telomere
silencing. Takahashi et al. (2011) took an alternative
approach by analyzing natural telomere position–effect
variegation and show that the role of Dot1 in heterochro-
matin formation is telomere-specific. Nevertheless, in-
terplay between Sir proteins and Dot1 does serve to
Nguyen and Zhang
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regulate heterochromatin formation at telomeres, but
perhaps to a lesser extent than originally thought.
Genome-wide analysis links H3K79me
to active transcription
In addition to participating in telomere silencing, ge-
nome-wide analysis of H3K79 methylation has linked
this modification to transcription. Approximately 10% of
the yeast genome is hypomethylated at H3K79 and bound
by Sir proteins (Laurenson and Rine 1992; van Leeuwen
et al. 2002), which is consistent with the fact that meth-
ylated H3K79 inhibits Sir binding (Onishi et al. 2007; van
Welsem et al. 2008). Meanwhile, 90% of the yeast genome
bears H3K79 methylation and is actively transcribed
(Laurenson and Rine 1992; van Leeuwen et al. 2002),
suggesting that H3K79 methylation is a marker of eu-
chromatin. In support of this notion, work by Ng et al.
(2003a) showed that H3K79 methylation correlates with
euchromatin at sites of active V(D)J recombination, while
hypomethylation is found at inactive loci.
The development of high-throughput technology to
map specific chromatin modifications on a genome-wide
scale has provided an invaluable method to further de-
cipher the role of H3K79 methylation in transcriptional
regulation. In Drosophila, chromatin immunoprecipita-
tion (ChIP) coupled with gene expression microarray
(ChIP–chip) revealed that histone acetylation, H3K4me2,
H3K4me3, and H3K79me2 positively correlated with
active gene transcription (Schubeler et al. 2004). In con-
trast, another study using ChIP–chip demonstrated in S.
cerevisiae that, although H3K79me3 is enriched within
transcribed gene regions, there was no correlation be-
tween the level of H3K79me3 and transcriptional activ-
ity (Pokholok et al. 2005). This was further supported by
Zhao and colleagues (Barski et al. 2007) using ChIP
coupled with deep sequencing (ChIP-seq) to map mono-,
di-, and trimethyl H3K79 in human CD4+ T cells. They
found a slight correlation between H3K79me1 and gene
activation. However, H3K79me3 was more closely asso-
ciated with gene repression, while H3K79me2 did not
correlate with transcriptional status (Barski et al. 2007).
These two genome-wide analyses were inconsistent with
previous studies linking H3K79 methylation to active
gene transcription (Ng et al. 2003a; Schubeler et al. 2004;
Okada et al. 2005, 2006; Vakoc et al. 2006).
The discrepancy between different genome-wide pro-
filing studies was later attributed to different methods
used for chromatin preparation. The two reports showing
no correlation between H3K79 methylation and tran-
scriptional activity performed ChIP in the absence of
sodium dodecyl sulfate (SDS), which is required for proper
detection of H3K79 methylation in formaldehyde-cross-
linked chromatin (Steger et al. 2008). Accordingly, ChIP–
chip using mouse 3T3 cells demonstrates that all H3K79
methylation marks are localized within the body of
transcribed genes, and that the amount of enrichment
correlates with expression level (Steger et al. 2008). Sub-
sequently, following the revised ChIP protocol, Zhao and
colleagues (Wang et al. 2008) published a second genome-
wide study, again using human CD4+ T cells, which
confirmed the findings by Steger et al. (2008). Collec-
tively, analyses of yeast, mouse, fly, and human genomes
revealed that H3K79 methylation is indeed a marker of
active transcription.
Role of Dot1L in transcriptional elongation
The genome-wide localization studies revealed that
H3K79 methylation is enriched in gene coding regions
(Kouskouti and Talianidis 2005), implicating a potential
role for Dot1 in transcriptional elongation. Consistent
with this notion, the Paf1 complex, which is associated
with elongating RNA polymerase II (Pol II), regulates
Dot1 H3K79 methyltransferase activity (Krogan et al.
2003). In addition, involvement of DOT1L in transcrip-
tional elongation is supported by the purification of various
mammalian DOT1L-containing complexes, which are
summarized in Table 1.
The first DOT1L-associated complex, termed ENL-
associated proteins (EAPs), was purified by immunopre-
cipitation using antibodies against ENL. In addition to
ENL, the complex contains A4F, AF5q31, LAF4, DOT1L,
P-TEFb, Ring1, CBX8, and BCoR (Mueller et al. 2007). A
more recent study indicated that the core EAP complex
consists of only ENL, AF4, DOT1L, and P-TEFb (Mueller
et al. 2009). P-TEFb is a cyclin-dependent kinase com-
plex that phosphorylates Ser2 within the RNA Pol II
C-terminal domain (CTD). This phosphorylation event is
required for the transition of RNA Pol II from transcription
initiation to the transcription elongation phase. The puri-
fied EAP complex possesses both H3K79 methyltransferase
Table 1. Comparison of the composition of the DOT1L-relevant transcriptional elongation complexes
Proteins
Complex DOT1L AF4 AF5q31 AF9 AF10 ENL P-TEFb Other Reference
EAP + + + + + LAF4, Ring1, CBX8, BCoR Mueller et al. 2007
EAP core + + + + Mueller et al. 2009
Bitoun et al. 2007 + + + + + + Bitoun et al. 2007
DotCom + + + + AF17, TRRAP, Skp1,
B-catenin
Mohan et al. 2010
SEC + + + ELLs, AFF4 Lin et al. 2010
AEP + + + + Yokoyama et al. 2010
Plus sign indicates that the protein was purified in the listed complex.
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and RNA Pol II CTD kinase activities. Importantly,
knockdown of ENL reduced genome-wide H3K79me2 as
well as global transcriptional elongation activity, suggest-
ing a link between H3K79 methylation and transcrip-
tional elongation (Mueller et al. 2007). The second
DOT1L-containing complex, which is related to EAP,
was purified by using an antibody against AF4 (Bitoun
et al. 2007). The complex contains AF4, AF9, AF10, ENL,
DOT1L, and P-TEFb. Importantly, overexpression of AF4,
AF9, ENL, and AF10 increased H3K79 methylation levels
and P-TEFb-dependent transcription elongation (Bitoun
et al. 2007). These studies collectively support a role for
DOT1L in transcriptional elongation.
In addition to the two related complexes mentioned
above, a recently purified DOT1L-containing compelx,
DotCom, contains members of the Wnt pathway in
addition to DOT1L, AF10, AF17, and AF9 (Mohan et al.
2010). Despite the absence of P-TEFb in this complex,
DOT1L was still required for the expression of Wingless
target genes, supporting its role in transcriptional activa-
tion (Mohan et al. 2010). Interestingly, another recently
purified superelongation complex (SEC) contains multiple
transcription elongation factors (ELL1–3, P-TEFb, AFF1/
AF4, AFF4, AF9, and ENL) and ELL-associated factors
(EAFs), but does not contain DOT1L (Lin et al. 2010).
Similarly, another elongation complex, AEP (which is
composed of AF4, AF5q31, ENL, and P-TEFb), also lacks
DOT1L (Yokoyama et al. 2010). It is likely that the
variation between different protein complexes purified
may result from the different methods and purification
procedures used in these studies. It is possible that
multiple transcriptional elongation complexes may exist,
and that DOT1L may associate with only a subset of elon-
gation complexes. Although DOT1L may not be required
for transcription of all genes, it certainly plays a role for
transcribing a subset of genes plausibly through facilitat-
ing transcriptional elongation. Based on available infor-
mation, we propose a model that encompasses sequential
events (including H2B-K123ub, H3K4me, H3K79me, and
RNA Pol II phosphorylation) that lead to transcriptional
activation and elongation (Fig. 3).
Role of Dot1 in DNA repair and cell cycle regulation
Role of Dot1 in the DNA damage response
Chromatin structure and nucleosome positioning, which
are dynamically regulated by histone modifications,
affect transcription by RNA Pol II. In addition, the pres-
ence of DNA damage, such as double-strand breaks (DSBs)
and lesions, can impede Pol II transcription elongation.
Therefore, mechanisms used in the regulation of chro-
matin conformation and transcription may also be used
in repairing DNA damage. Consistent with this notion,
studies in yeast and mammalian cells have established
a link between Dot1/DOT1L and their associated
H3K79 methylation to DNA damage checkpoint control
and repair.
The first evidence that suggested a link between
DOT1L-mediated H3K79 methylation and DNA damage
repair came from the demonstration that the tandem
tudor domain of the human 53BP1 protein binds to
methylated H3K79 and is recruited to DNA DSBs (Huyen
et al. 2004). Strikingly, both mutation of the tudor domain
and blocking H3K79 methylation through either mutat-
ing Lys 79 of H3 or knocking down DOT1L inhibited
recruitment of 53BP1 to DSBs. The interaction between
53BP1 and methylated H3K79 is evolutionarily conserved,
Figure 3. Mechanism for the involvement of DOT1L-mediated
H3K79 methylation in transcriptional elongation. For simplicity
of the model, only a fraction of the proteins involved in RNA Pol
II transcription is shown. In step I, RNA Pol II is phosphorylated
on Ser5 of its CTD and has initiated transcription. Negative
elongation factor (NELF) and 5,6-dichloro-1b-D-ribofuranosyl-
benzimidazole sensitivity-inducing factor (DSIF) are bound to
RNA Pol II for promoter-proximal pausing. In step II, promoter
clearance is achieved by the recruitment of P-TEFb, which
phosphorylates Ser2 of the RNA Pol II CTD, NELF, and DSIF.
Phosphorylated NELF dissociates to release Pol II. The PAF1
complex, along with RAD6 and BRE1, is recruited to ubiquiti-
nate H2B-K120. In step III, which can occur simultaneously
with step II, H3K4 di- and trimethylation is achieved by the
recruitment of MLL, the human homolog of Set1, by the PAF1
complex and association with H2B-K120ub. During transcrip-
tion elongation shown in step IV, DOT1L is recruited to
elongating RNA Pol II through its association with a network
of proteins that include, but are not limited to, the elongation
factors ELL, AF4, AF10, AF9, and ENL. DOT1L methylates
H3K79 to maintain active transcription and/or serve as a tran-
scription memory.
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as Rad9, the yeast ortholog of 53BP1, also binds to meth-
ylated H3K79 via its tudor domain (Wysocki et al. 2005).
Since H3K79 methylation levels do not change upon
DNA damage, it is believed that DSBs induce changes
in the chromatin structure to expose methylated H3K79,
which is then recognized by 53BP1 (Huyen et al. 2004).
However, given that Rad9 is still recruited to sites of
DSBs in the absence of the chromatin remodeling com-
plexes SWR and INO80 (Javaheri et al. 2006), further
studies are needed to prove or disprove this hypothetical
model.
Budding yeast cells treated with ionizing radiation (IR)
at G1 typically undergo a G1 checkpoint delay. Interest-
ingly, Dot1 mutants are defective in G1- and intra-
S-phase checkpoints and progress through the cell cycle
at a normal rate even after IR-induced DNA damage
(Wysocki et al. 2005). Moreover, mutations that affect
Dot1 enzymatic activity, such as disruption of H2B-K123
ubiquitination or mutation of H3K79, display the same
checkpoint defects in response to multiple genotoxic
stresses (Giannattasio et al. 2005; Game et al. 2006;
Chernikova et al. 2010). In response to IR damage, the
Dot1/Rad6/Bre1 pathway mediates DNA damage repair
through G1 homologous recombination (HR) (Game et al.
2006). Although Dot1 deletion mutants do not display
a G2 arrest phenotype (Game et al. 2006), Dot1 is required
for Rad9 recruitment to the damage foci and phosphory-
lation of Rad53 upon IR (Toh et al. 2006). Dot1-mediated
H3K79 methylation is believed to play two distinct roles
in Rad9-mediated DNA damage response (Grenon et al.
2007): the activation of the G1/S checkpoint, and the
repair of DNA damage at late G2 phase.
Repair of DSBs can occur via nonhomologous end-
joining (NHEJ) or HR. Resection of DSBs is an important
step in DNA damage repair by HR, producing 39 ssDNA
tail intermediates. It is believed that both H3K79 meth-
ylation and Rad9 recruitment play an integral role in
regulating resection to limit the amount of ssDNA that is
produced (Lazzaro et al. 2008). HR with the sister chro-
matid (SCR) in mitosis ensures faithful transmission of
the genetic material. A number of proteins, including
cohesin, are required for maintaining chromosome struc-
ture and for efficient SCR. Interestingly, not only is Dot1
required for the recruitment of Rad9 to the DSB sites and
for DNA resection, it also facilitates the recruitment of
cohesin and efficient SCR (Conde et al. 2009).
In addition to DSBs, Dot1-mediated H3K79 methyla-
tion plays a role in repairing other types of DNA lesions.
Ultraviolet radiation (UV) causes the formation of cis-syn
cyclopyrimidine and 6-4 photoproduct dimers, which can
be repaired by nucleotide excision repair (NER), recombi-
nation repair (RR), or post-replication repair (PRR). Dot1-
mediated H3K79 methylation plays a critical role in
repairing UV-induced DNA damage (Giannattasio et al.
2005), as loss of H3K79 methylation affects all three repair
pathways, resulting in UV hypersensitivity (Bostelman
et al. 2007; Lazzaro et al. 2008). When the base excision
repair (BER) pathway fails to repair damages caused by
alkylating agents, cell cycle progression and cell survival
may be achieved by the translesion synthesis (TLS)
pathway that uses error-prone polymerases to bypass
DNA lesions. Dot1 negatively regulates TLS, thereby
maintaining genome integrity upon DNA damage (Conde
and San-Segundo 2008; Conde et al. 2010; Levesque et al.
2010).
Beyond its role in the DNA damage response, Dot1 is
also important for meiotic checkpoint control. Diploid
parental cells undergo meiotic cell division to generate
haploid gametes. Proper segregation of chromosomes
during meiosis is ensured by the pachytene checkpoint,
which monitors completion of chromosome synapsis and
recombination to prevent premature nuclear division. In
the event of defective meiotic recombination, the pachy-
tene checkpoint induces arrest at mid-meiotic prophase.
In yeast, arrest at pachytene can be observed in dmc1
and zip1 mutants, which are required for proper synapsis
formation and repair of DSBs. In a genetic screen for
pachytene checkpoint components, dmc1 and zip1 mu-
tants failed to arrest in the absence of Dot1. This failure
to arrest is partially due to mislocalization of the nucle-
olar proteins Pch2 and Sir2, both of which are required for
pachytene checkpoint function (San-Segundo and Roeder
2000). Collectively, an overwhelming amount of data
support a vital role for Dot1 in regulating cell cycle
progression in yeast upon DNA damage (Fig. 4). Surpris-
ingly, very little work has been done to determine
whether Dot1’s role in DNA damage checkpoint control
is conserved in mammals.
Cell cycle-regulated H3K79 methylation
Being able to repair damaged DNA is vital for maintain-
ing genome integrity and stability. DNA repair occurs
upon checkpoint activation as a cell progresses through
the cell cycle phases: G1, S, G2, and M. Consistent with
its role in the DNA damage repair pathways, H3K79
methylation levels fluctuate with the cell cycle. In yeast,
H3K79me2 levels are low in G1 and S, begin to increase in
late S, and are maintained relatively higher in G2 and M
phases (Schulze et al. 2009). Paradoxically, a greater
percentage of dot1D cells accumulate in G1 (a period
with low H3K79me2) compared with wild-type cells.
Despite the general correlation between H3K79me2
levels and transcription activity, genes that are expressed
specifically in G1 (when H3K79me2 is low) are enriched
with H3K79me2 during G2/M (Schulze et al. 2009). These
data suggest that, at least in this subset of genes,
H3K79me2 is inversely correlated with gene activity
and may have a role in epigenetic memory (Schulze et al.
2009). However, the cell cycle-dependent variation of
H3K27me2 levels in HeLa cells is different from that
observed in yeast. In HeLa cells, the H3K79me2 level is
high in G1, decreases in S, reaches the lowest in G2, and
increases again in M phase (Feng et al. 2002). Thus, it is
apparent that the role of cell cycle-regulated H3K79me2
changes in yeast is not evolutionarily conserved in humans.
Mouse DOT1L has also been implicated in cell cycle
progression of differentiating embryonic stem (ES) cells
and erythroid progenitor cells. Although DOT1L-de-
pleted ES cells retain their proliferation and pluripotency
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capacity, they displayed severe proliferation defects upon
RA-induced in vitro differentiation, resulting in G2/M
accumulation (Barry et al. 2009). Interestingly, both un-
differentiated and differentiated DOT1L knockdown
ES cells exhibited aneuploidy, with the phenotype being
more pronounced upon differentiation (Barry et al. 2009).
Consistent with this, DOT1L knockout ES cells also
displayed a G2/M cell cycle defect and aneuploidy (Jones
et al. 2008). Interestingly, apoptosis was observed in
DOT1L knockout ES cells (Jones et al. 2008), but was
absent in knockdown cells (Barry et al. 2009). In addition
to mouse ES cells, DOT1L plays an important role in cell
cycle progression and antagonizing apoptosis in primitive
erythroid progenitor cells (Jones et al. 2008). In contrast
to that observed in ES cells, DOT1L knockout in the
erythroid lineage results in an accumulation at G0/G1
rather than G2/M (Feng et al. 2010), indicating that the
cell cycle effect of DOT1L might be cell type-specific.
Further studies are needed to understand why cell cycle
regulation by Dot1 and DOT1L are organism and cell
type-dependent.
Biological functions of DOT1L
Role of Dot1 in embryonic development
In addition to the studies performed in cell lines and
lower eukaryotes, the role of Dot1-mediated H3K79
methylation was also analyzed in higher eukaryotes,
including animals. For example, the cell cycle regulation
of H3K79 methylation levels observed in cell lines is also
observed during embryogenesis. During fly embryogene-
sis, methylation of H3K79 is absent in both transcrip-
tionally active somatic nuclei and quiescent pole cell
nuclei at the precellular blastoderm. H3K79me2 begins
to emerge after gastrulation at the germband extended
embryo stage 8/9 and is restricted to cells undergoing
mitosis (Shanower et al. 2005). Increasing levels of
H3K79me2 are then observed in epidermal nuclei during
dorsal closure and head involution. The re-establishment
of H3K79me2 suggests that this modification plays an
important role in regulating transcription of developmen-
tal genes (Shanower et al. 2005). Interestingly, mutation
of Grappa, the fly ortholog of Dot1, causes phenotypes
observed in both Polycomb Group (PcG) and trithorax
Group (trxG) mutants (Shanower et al. 2005). PcG and
trxG genes play antagonistic roles by respectively silenc-
ing and activating the expression of Antennapedia and
Bithorax homeotic genes, which specify anterior-to-pos-
terior parasegmentation identity (Ringrose and Paro
2004). In addition to a role in parasegmentation, Grappa
has been implicated in Wnt/Wingless signaling, which is
required for morphogenesis in wing imaginal discs
(Mohan et al. 2010). Using knockdown approaches, Grappa
was shown to regulate the active expression of Wingless
target genes such as senseless, frizzled 3, and homothorax
(Mohan et al. 2010). Taken together, the data indicate that
Grappa may play a dual role in regulating both the active
and silenced states of specific chromatin domains during
fly development.
Similar to that observed in Drosophila, H3K79 meth-
ylation is also absent from mouse zygotes and is present
at a very low level until the blastocyst stage (Ooga et al.
2008), suggesting that loss of this epigenetic mark is im-
portant for early embryogenesis. Although H3K79me2
is detectable from the four-cell to blastocyst stages,
H3K79me3 is undetectable even at the blastocyst stage
(Ooga et al. 2008). Germline knockout of mDOT1L
results in lethality by embryonic day 10.5 (E10.5) during
organogenesis of the cardiovascular system (Jones et al.
2008). Consistently, knockout embryos display cardio-
vascular defects, including heart enlargement, decreased
Figure 4. Role of Dot1 in DNA damage checkpoint response
and repair. The yeast proteins are shown, and the steps in which
Dot1 has been implicated are marked by red stars. (A) In yeast,
the PI-3 kinases Mec1/Ddc2 (human ATR/ATRIP) sense exposed
ssDNA formed during repair of UV-, oxidative-, and alkylating-
damaged DNA as well as resected DSBs. The sensor PI-3 kinase
Tel (human ATM) recognizes blunt-end DSBs. After recognition
and binding of sensor proteins to the site of DNA damage,
mediator proteins such as Rad9, Dpb11, and Mrc1 are recruited
and activated by phosphorylation. Dot1-mediated H3K79 meth-
ylation is required for the recruitment and activation of Rad9
and phosphorylation of the downstream transducer protein
Rad53. Dot1 is also required for proper checkpoint function at
both G1 and G2. (B) Several different DNA repair mechanisms
can be used by the cell in response to different types of DNA
damage. Damage by UV radiation can be repaired by NER, RR,
and PRR. Loss of H3K79 methylation impairs all three path-
ways, resulting in hypersensitivity to UV damage. Damage by
alkylating agents can be repaired by the BER pathway. In rare
instances where the damage cannot be repaired, the error-prone
TLS pathway can be activated to bypass the DNA lesion. It was
demonstrated that Dot1 maintains DNA integrity by inhibiting
TLS. Finally, IR, which generates DSBs, can be repaired by
NHEJ. Alternatively, the DSBs can undergo 59-to-39 resection
and be repaired by HR. Methylation of H3K79 and the sub-
sequent recruitment of Rad9 are required for regulating re-
section. Additionally, H3K79 methylation is required for the
recruitment of cohesin, which is important for maintaining
chromosome structure and for efficient SCR to repair DSBs.
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vasculature, and anemia (Jones et al. 2008). These studies
collectively demonstrate that DOT1L and Grappa play an
important role in embryonic development in mice and
Drosophila, respectively.
Role of DOT1L in cardiac function
The cardiovascular defect observed in mDOT1L knock-
out embryos (Jones et al. 2008) suggested that mDOT1L
may play a role in cardiac development, which is consis-
tent with ex vivo studies demonstrating a correlation
between increased H3K79 methylation and induced ex-
pression of cardiovascular marker genes during myocar-
diogenesis (Illi et al. 2005). To elucidate the role of
mDOT1L in cardiac development and function, we gen-
erated a cardiac-specific knockout mouse model by
crossing floxed Dot1l mice with a-myosin heavy chain-
Cre mice (Nguyen et al. 2011b). Cardiac-specific knock-
out of mDOT1L caused dilated cardiomyopathy (DCM)
(Nguyen et al. 2011b), a disease of the heart muscle
manifested by chamber dilation and systolic dysfunction.
Mechanistically, mDOT1L-mediated H3K79 methyla-
tion directly regulates transcription of dystrophin (Fig.
5). Given that dystrophin is required for forming the
dystrophin–glycoprotein complex (DGC) that is involved
in signal force transmission and relieving mechanical
stress during heart contraction, loss of dystrophin expres-
sion causes DGC destabilization, resulting in sarcolemma
damage (Kimura 2008). In humans, dystrophin mutations
are a known cause of human DCM and muscular dys-
trophy. Importantly, the DCM phenotype observed in
mDOT1L cardiac-specific knockout mice can be rescued
by ectopic expression of a functional truncated form of
dystrophin (Nguyen et al. 2011b), indicating that dystro-
phin is a major downstream target that mediates the
cardiac function of DOT1L. Interestingly, analysis of
DOT1L expression levels revealed that DOT1L is signif-
icantly lower in human idiopathic DCM heart tissue
compared with normal heart tissue (Nguyen et al. 2011b),
raising the possibility that malfunction of DOT1L may be
a contributing factor in human DCM pathogenesis.
Role of DOT1L in erythropoiesis
In addition to cardiovascular defects, DOT1L knockout
embryos display severe anemia by E10.5, suggesting
impaired fetal erythropoiesis (Feng et al. 2010). A possible
role for mDOT1L in erythropoiesis would be consistent
with a previous report demonstrating that H3K79 meth-
ylation is enriched at the erythroid-specific b-globin locus
(Im et al. 2003). In support of this, mDOT1L deficiency in
yolk sac-derived hematopoietic cells caused a G0/G1 cell
cycle arrest and induced apoptosis in erythroid progenitor
cells cultured in vitro in the presence of growth stimuli,
but had no effect on myeloid lineage growth and differ-
entiation (Feng et al. 2010). RT-qPCR and ChIP analyses
indicated that the function of mDOT1L in erythropoiesis
was mediated by its role in activation of Gata2. The
down-regulation of Gata2 in Dot1l-deficient hematopoi-
etic cells caused derepression of the myeloid transcrip-
tion factor PU.1 to block erythroid differentiation (Feng
et al. 2010).
Role of DOT1L in leukemia
It is apparent that DOT1L is vital for normal cellular and
biological processes, including DNA damage repair, cell
cycle, development, cardiac muscle function, and hema-
topoiesis. However, transcriptional activation by DOT1L-
mediated H3K79 methylation is also exploited in leuke-
mias that stem from chromosomal rearrangements of MLL
(mixed-lineage leukemia). This misregulation of DOT1L
is achievable because components of the elongation com-
plexes EAP (Mueller et al. 2007), SEC (Lin et al. 2010), and
AEP (Yokoyama et al. 2010) interact with DOT1L and are
frequent translocation partners of MLL (Ayton and Cleary
2001). Translocation of the MLL gene results in the
expression of oncogenic fusion proteins and is a common
cause of acute leukemia (Ayton and Cleary 2001; Hess
2004), accounting for 5%–10% of adult acute leukemias
(Daser and Rabbitts 2004) and 60%–80% of infant acute
leukemias (Ayton and Cleary 2001; Hess 2004; Krivtsov
and Armstrong 2007).
Figure 5. DOT1L contributes to cardiac function
by activating dystrophin expression. DOT1L-medi-
ated H3K79 methylation is required for dystrophin
expression. Dystrophin forms a DGC that plays
a pivotal role in lateral force transduction and re-
lieving mechanical stress for optimal cardiac perfor-
mance. Loss of H3K79 methylation results in
silencing of the dystrophin locus, loss of expression
of the DGC complex, and sarcolemma damage. The
absence of a functional DGC is manifested by
systolic dysfunction and DCM.
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MLL is an H3K4 methyltransferase that maintains the
‘‘on’’ state of Hox genes during embryogenesis and hema-
topoiesis (Hsieh et al. 2003; Guenther et al. 2005). In
leukemia, Hoxa genes remain constitutively active to
promote uncontrolled proliferation of leukemic cells.
Although MLL fusion proteins lack the catalytic SET
domain (Fig. 6A), it is believed that constitutive activa-
tion of leukemic oncogenes is mediated by wild-type
MLL expressed from the nonmutated allele, as well as the
transactivation activity of the MLL fusion partner and
other recruited factors such as MENIN (Yokoyama et al.
2005) and LEDGF (Yokoyama and Cleary 2008). Due to
the high incidence of MLL-related acute leukemias,
a better understanding of the molecular mechanisms
used by MLL fusion proteins is vital for the development
of effective treatments. However, the heterogeneity of
>50 MLL fusion partners makes targeted therapy for
MLL-related leukemias difficult.
The first evidence that suggested a role for DOT1L in
leukemia came from studies looking for functional part-
ners of DOT1L. A yeast two-hybrid screen identified two
MLL fusion partners—AF10 and ENL—as DOT1L-inter-
acting proteins (Okada et al. 2005). Further characteriza-
tion of the AF10 and DOT1L interaction mapped the
interaction domain to the OM-LZ region of AF10 required
for the transformation activity of MLL-AF10, raising the
possibility that AF10 serves as a bridge for the recruit-
ment of DOT1L to MLL-AF10 target genes (Okada et al.
2005). This scenario gained experimental support, as both
MLL-AF10 and H3K79me2 were specifically enriched at
the Hoxa9 locus in MLL-AF10-transformed cells com-
pared with control cells. Importantly, overexpression of
Hoxa9 as well as the transformation capability of MLL-
AF10 were dependent on DOT1L enzymatic activity.
Moreover, Hoxa9 was shown to be a critical downstream
target of MLL-AF10, as deletion of the Hoxa9 gene pre-
vented transformation by MLL-AF10 (Okada et al. 2005).
These studies suggest that mistargeting of DOT1L by
MLL-AF10 and the subsequent H3K79 methylation and
activation of oncogenes such as Hoxa9 are the mech-
anisms underlying DOT1L’s contribution to transforma-
tion, and raise the possibility that DOT1L may be a good
target for therapeutic intervention. In a follow-up study,
the same mechanism was also shown for DOT1L’s con-
tribution to CALM-AF10-mediated transformation (Okada
et al. 2006). However, Hoxa5, instead of Hoxa9, is the
relevant downstream target for CALM-AF10, as bone
marrow cells deficient for Hoxa5 cannot be transformed
by CALM-AF10, but bone marrow cells deficient for
Hoxa9 can (Okada et al. 2006).
In addition to MLL-AF10 and CALM-AF10, DOT1L
is involved in transformation by other MLL fusion pro-
teins, such as MLL-ENL (Mueller et al. 2007), MLL-AF4
(Krivtsov et al. 2008), and MLL-AF9 (Chang et al. 2010;
Nguyen et al. 2011a). Consistent with the fact that DOT1L
is involved in MLL-related transformation, DOT1L asso-
ciates with a number of MLL fusion proteins and partic-
ipates in the activation of a leukemic transcriptional
program (Bitoun et al. 2007; Mueller et al. 2007, 2009).
The exact mechanism regarding how DOT1L contributes
to the gene activation process requires further elucidation;
however, it is clear that DOT1L is broadly involved in
leukemogenesis, particularly those mediated by MLL
fusion proteins such as AF4, AF9, AF10, and ENL, which
account for two-thirds of all MLL-associated leukemias
(Ayton and Cleary 2001).
The above studies collectively establish a broad role for
DOT1L in transformation, and suggest a general mecha-
nism by which DOT1L contributes to the leukemogene-
sis process (Fig. 6B). Interaction between DOT1L and
MLL fusion partners leads to mistargeting of DOT1L to
the gene targets of MLL fusion proteins, such as the Hoxa
cluster and Meis1. Aberrant hypermethylation of H3K79
leads to constitutive transcriptional activation of these
genes, which in turn results in leukemic transformation.
Inhibition of DOT1L enzymatic activity or disruption of
the interaction between DOT1L and the MLL fusion
proteins may provide a promising therapeutic strategy
for the treatment of MLL fusion-related leukemias. How-
ever, given the role of DOT1L in normal hematopoiesis
(Feng et al. 2010; Jo et al. 2011), the possible side effects of
such drugs have to be carefully evaluated before they can
be used in the treatment of leukemia patients.
Figure 6. MLL fusion proteins recruit DOT1L for transcrip-
tional activation and leukemogenesis. (A, top) MLL is a SET
domain-containing H3K4 methyltransferase with multiple func-
tional domains. (AT-hook and CxxC) DNA binding; (SNL) signal
nuclear localization; (PHD) protein interactions; (TAD) trans-
activation domain; (SET) methyltransferase domain. Frequent
DSBs occur within the MLL locus at a breakpoint cluster region
(BCR). (Bottom) The N terminus of MLL undergoes chromo-
somal rearrangements and fuses in-frame to >50 different genes,
resulting in the expression of leukemogenic MLL fusion pro-
teins. (B) Constitutive activation of a leukemic transcriptional
program, including Hoxa and Meis1 genes, is achieved through
mistargeting of DOT1L and its associated proteins through the
interaction of DOT1L with MLL fusion partners. DOT1L-
mediated H3K79 methylation and the subsequent activation
of the target genes result in leukemic transformation.
Nguyen and Zhang
1354 GENES & DEVELOPMENT
Concluding remarks
Dot1 is unique not only in its structure, but in its substrate
specificity. Although its catalytic domain resembles that
of class I arginine methylases, Dot1 methylates histone H3
at Lys 79. H3K79 is also located within the surface-exposed
globular domain of H3 rather than its NH3 tail, where all
other known methylation residues reside. Paradoxically,
Dot1-mediated H3K79 methylation is capable of regulat-
ing transcription at both heterochromatin and euchroma-
tin. Globally, H3K79 methylation is enriched in actively
transcribing genes. Consistently, H3K79 methylation is
required for the expression of Wnt target genes in Dro-
sophila imaginal discs, dystrophin in cardiac and myoblast
cells, and the Hoxa cluster in leukemic cells.
Intriguingly, Dot1 is the sole H3K79 methylase capable
of catalyzing mono-, di-, and trimethylation in a non-
processive manner. Thus, in the absence of any other
mediator proteins, the likelihood of an H3K79me1 mark
becoming H3K79me2 and an H3K79me2 mark becoming
H3K79me3 have the same probability. If this were the
case, it could be inferred that they all play redundant roles
in regulating transcription, and brings into question the
need for different H3K79 methylation states (Frederiks
et al. 2008). Nevertheless, studies suggest that the various
H3K79 methylation states have different functions in
transcriptional regulation and/or other processes. For ex-
ample, in yeast, only H3K79me2 fluctuates with the cell
cycle, whereas H3K79me3 levels remain constant. Addi-
tionally, in early mouse embryogenesis, H3K79me2 and
H3K79me3 emerge at distinct stages of development.
How the same enzyme achieves specificity to temporally
regulate its catalytic activity at specific chromatin do-
mains remains to be determined. One possibility is that
its enzymatic activity might be regulated by other pro-
teins, such as Rad6/Bre1 and the Paf1 complex in yeast
and other associated proteins identified in mammals. An-
other possibility is that the steady-state levels of H3K79
methylation might be regulated by a putative H3K79
demethylase.
In addition to transcription, Dot1 plays an important
role in cell cycle regulation and the DNA damage re-
sponse. Furthermore, mammalian DOT1L is an essential
gene that is required for embryogenesis, hematopoiesis,
and cardiac function. Finally, DOT1L plays a pivotal role
in MLL-related leukemogenesis. Given the importance
of its enzymatic activity in these processes, DOT1L
emerges as a promising target for therapeutic treatments.
It is apparent that DOT1L and its associated H3K79
methylation activity are extremely complex. As such,
the regulation of DOT1L enzymatic activity and the
functional consequences need to be further elucidated
before efficient treatments can be developed. We expect
that future studies will reveal details regarding how its
enzymatic activity is regulated, and how H3K79 methyl-
ation leads to transcriptional activation. We also antici-
pate a revelation of DOT1L functions outside the cardio-
vascular and hematopoietic systems. Identification and
characterization of DOT1L inhibitors and evaluation of
their efficacy in leukemia treatment will provide another
example where initial inquiry into the function of a basic
histone modification leads to a treatment for a deadly
disease.
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